Home » Stocks » CNTG

Centogene N.V. (CNTG)

Stock Price: $11.65 USD 0.10 (0.87%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $12.13 +0.48 (4.12%) Jan 19, 5:48 PM
Market Cap 252.50M
Revenue (ttm) 54.81M
Net Income (ttm) -23.21M
Shares Out 19.86M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $11.65
Previous Close $11.55
Change ($) 0.10
Change (%) 0.87%
Day's Open 11.85
Day's Range 11.45 - 12.14
Day's Volume 113,035
52-Week Range 9.30 - 25.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare dis...

Seeking Alpha - 1 month ago

Seeking Alpha Transcripts | Healthcare Centogene N.V. (CNTG) CEO Andrin Oswald on Q3 2020 Results - Earnings Call Transcript Dec. 16, 2020 2:58 PM ET | | About: Centogene N.V. (CNTG) by: SA Tr...

Benzinga - 1 month ago

Shares of Centogene (NASDAQ:CNTG) remained unaffected in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 97.88% year over year to ($0.30)...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare dis...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wor...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...

GlobeNewsWire - 1 month ago

Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional Countries Expanded Partnersh...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world cli...

GlobeNewsWire - 2 months ago

GENT, Belgium and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that tr...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and BAARN, the Netherlands, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare disease...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-...

Seeking Alpha - 3 months ago

Centogene N.V. (CNTG) CEO Arndt Rolfs on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare ...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-w...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., and ROSTOCK, Germany & BERLIN, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-w...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announc...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases th...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., and ROSTOCK and BERLIN, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clin...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 23, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world c...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene” or the “Company”), a commercial-stage company focused on rare d...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announce...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass. and SANTA MONICA, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, and the OESIS Network...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 02, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...

Zacks Investment Research - 6 months ago

Centogene (CNTG) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Benzinga - 6 months ago

Shares of German genetic diagnosis company Centogene NV (NASDAQ: CNTG) were advancing strongly Monday.

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 29, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world c...

GlobeNewsWire - 6 months ago

Cambridge, Mass. and ROSTOCK, Germany and BERLIN, June 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...

Seeking Alpha - 7 months ago

Centogene N.V. (CNTG) CEO Arndt Rolfs on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 15, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass. and BERLIN and ROSTOCK, Germany, May 15, 2020 (GLOBE NEWSWIRE) -- Centogene N.V (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., USA, ROSTOCK, Germany and BERLIN, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transfo...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 08, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world cl...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 06, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world cl...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN,, May 05, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world c...

Seeking Alpha - 8 months ago

Centogene N.V. (CNTG) CEO on Arndt Rolfs Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 21, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world ...

GlobeNewsWire - 9 months ago

ROSTOCK, Germany and COLOGNE, Germany, April 17, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical an...

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Germany, April 15, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms re...

Zacks Investment Research - 9 months ago

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

Other stocks mentioned: ARKG, AYTU, BBH, CNCR, CODX, FTSV, IBB, IDNA, VIR
GlobeNewsWire - 10 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Germany, March 18, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms r...

GlobeNewsWire - 10 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 17, 2020 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-w...

GlobeNewsWire - 10 months ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG) ─ The Company today announced that Dr. Dirk H. Ehlers, COO and President of its ...

About CNTG

Centogene N.V., together with its subsidiaries, engages in diagnosis and research around rare diseases that transform clinical and genetic data into information for patients, physicians, and pharmaceutical companies. Its platform analyzes epidemiologic, phenotypic, and genetic data to enhance the understanding of rare hereditary diseases. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment provides various services, including target discovery, early patient recruitment and identification, epidem... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 7, 2019
Stock Exchange
NASDAQ
Ticker Symbol
CNTG
Full Company Profile

Financial Performance

In 2019, Centogene's revenue was 48.78 million, an increase of 20.51% compared to the previous year's 40.48 million. Losses were -20.66 million, 88.3% more than in 2018.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Centogene stock is "Strong Buy." The 12-month stock price forecast is 20.84, which is an increase of 78.88% from the latest price.

Price Target
$20.84
(78.88% upside)
Analyst Consensus: Strong Buy